The seeding of scaffolds with adipose tissue-derived microvascular fragments represents a promising strategy to establish a sufficient blood supply in tissue constructs. Herein, we analysed whether a single application of macrophage-activating lipopeptide-2 (MALP-2) at the implantation site further improves the early vascularisation of such microvessel-seeded constructs. Microvascular fragments were isolated from epididymal fat pads of C57BL/6 mice. The fragments were seeded on polyurethane scaffolds, which were implanted into mouse dorsal skinfold chambers exposed to MALP-2 or vehicle (control). The inflammatory host tissue response and the vascularisation of the scaffolds were analysed using intravital fluorescence microscopy, histology and immunohistochemistry. We found that the numbers of microvascular adherent leukocytes were significantly increased in MALP-2-treated chambers during the first 3 days after scaffold implantation when compared to controls. This temporary inflammation resulted in an improved vascularisation of the host tissue surrounding the implants, as indicated by a higher density of CD31-positive microvessels at day 14. However, the MALP-2-exposed scaffolds themselves presented with a lower functional microvessel density in their centre. In addition, in vitro analyses revealed that MALP-2 promotes apoptotic cell death of endothelial and perivascular cells in isolated microvascular fragments. Hence, despite the beneficial pro-angiogenic properties of MALP-2 at the implantation site, the herein evaluated approach may not be recommended to improve the vascularisation capacity of microvascular fragments in tissue engineering applications.
Introduction
The rapid establishment of a sufficient vascularisation is a crucial prerequisite for the survival of implanted tissue constructs (Novosel et al., 2011; Auger et al., 2013; Rouwkema and Khademhosseini, 2016) . We and others have shown that this may be achieved by the seeding of tissue constructs with adipose tissue-derived microvascular fragments prior to their implantation (Hiscox et al., 2008; Laschke et al., 2012; Pilia et al., 2014) .
Microvascular fragments are a mixture of arteriolar, capillary and venular vessel segments, which can be isolated by enzymatic digestion of fat tissue (Hoying et al., 1996; Shepherd et al., 2004; Nunes et al., 2010) . The fragments release pro-angiogenic growth factors, such as vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) (Laschke et al., 2012; Pilia et al., 2014) . In addition, they are a rich source of mesenchymal stem cells and endothelial progenitor cells (Laschke et al., 2012; McDaniel et al., 2014) . After their incorporation into scaffolds they reassemble to functional microvascular networks during the first 6 d after implantation (Laschke et al., 2012) . In the present study, we speculated that this initial period, which is characterised by critical hypoxia within the implants, may be further shortened by local application of macrophage-activating lipopeptide-2 (MALP-2) at the implantation site.
MALP-2 is a toll-like receptor (TLR) 2/6 agonist originating from mycoplasma species, which is a potent stimulator of the immune system (Mühlradt et al., 1997) . Accordingly, the compound has been suggested as a suitable mucosal adjuvant for vaccination (Rharbaoui et al., 2002; Lührmann et al., 2005) and inducer of lipopolysaccharide cross tolerance (Deiters et al., 2003) . More recent studies demonstrate that MALP-2 promotes angiogenesis by up-regulation of granulocyte-macrophage colony-stimulating factor (GM-CSF) (Grote et al., 2010) and improves re-endothelialisation after vascular injury (Grote et al., 2013a) . Importantly, the angiogenic potential of MALP-2 has been shown in vitro and in vivo to be comparable to that of VEGF and bFGF (Grote et al., 2010) . In addition, we found that the early vascular ingrowth into porous polyethylene (Medpor ® ) scaffolds is markedly improved by local single-shot application of MALP-2 at the implantation site (Laschke et al., 2014a) . In contrast to the coating of scaffolds with angiogenic growth factor delivery systems, the local single-shot application of MALP-2 at the implantation site may be particularly attractive for clinical purposes, because it does not involve complex biological implant modifications. Moreover, the stimulation of angiogenesis by MALP-2 is partly mediated by a short-term accumulation and activation of immune cells (Laschke et al., 2014a) , which may increase bacterial clearance and, thus, reduce the risk of implant infections. Finally, MALP-2 has already been proven to enhance wound healing (Niebuhr et al., 2008) and to suppress tumour growth (Schmidt et al., 2007) in clinical phase I/II studies without inducing systemic side effects. However, the effects of MALP-2 on the vascularisation of scaffolds seeded with microvascular fragments have not been analysed so far.
Therefore, we herein seeded polyurethane scaffolds with microvascular fragments, which were implanted into MALP-2-or vehicle-treated mouse dorsal skinfold chambers. The angiogenic and inflammatory host tissue response to the implants was analysed by means of repetitive intravital fluorescence microscopy, histology and immunohistochemistry over an observation period of 14 d.
Materials and Methods

Animals
This study was approved by the local governmental animal care committee. All animal experiments were conducted in accordance with the German legislation on protection of animals and the NIH Guidelines for the Care and Use of Laboratory Animals (NIH Publication #85-23 Rev. 1985) .
We used male C57BL/6 mice with an average age of 8 months and a body weight of 30-35 g as donors for the isolation of microvascular fragments to guarantee large epididymal fat pads and, thus, sufficient amounts of microvascular fragments for the seeding of the scaffolds. Dorsal skinfold chambers were implanted into C57BL/6 mice with an average age of 3-4 months and a body weight of 22-26 g (Institute for Clinical & Experimental Surgery, Saarland University, Homburg/Saar, Germany), to guarantee optimal implantation conditions. The animals were housed one per cage and had free access to tap water and standard pellet food throughout the experiments (Altromin, Lage, Germany).
Isolation of microvascular fragments and seeding of scaffolds
For the isolation of microvascular fragments, donor mice were anaesthetised by intraperitoneal (i.p.) injection of ketamine (75 mg/kg body weight; Pharmacia GmbH, Erlangen, Germany) and xylazine (25 mg/kg body weight; Rompun, Bayer, Leverkusen, Germany). Subsequently, the two epidydimal fat pads were carefully excised by means of a microscissors and enzymatically digested, as described previously in detail (Laschke et al., 2012) . Directly after the isolation procedure, we assessed the number of microvascular fragments from 2 donor animals by means of a Leica microscope with digital camera (Leica DM IL; Leica Microsystems, Wetzlar, Germany) and computer-assisted analysis system (Leica Application Suite 4.8; Leica Microsystems). Our analysis revealed that 16,165 ± 545 microvascular fragments per donor animal could be isolated. This was also the number of fragments which was seeded per scaffold.
The microvascular fragments were seeded on porous nano-size hydroxyapatite particles/poly(ester-urethane) composite scaffolds, which have originally been generated for bone tissue engineering applications (Laschke et al., 2010) . These scaffolds exhibit a size of ~ 3 × 3 × 1 mm and interconnected macropores of ~ 220 µm. Thus, they ideally support vascular ingrowth and can be used as standardised matrices for the evaluation of different vascularisation approaches (Laschke et al., 2013) .
For the seeding of the scaffolds with microvascular fragments, they were fixed in the lumen of a modified 1 mL syringe (BD Plastipak; BD Biosciences, Heidelberg, Germany), as described previously in detail (Laschke et al., 2014b) . The tip of the syringe was filled with 20 µL PBS containing the microvascular fragments. Negative and positive pressure was alternately induced three to five times in the syringe so that the microvascular fragments passed the scaffolds from both sides and were finally trapped in the scaffold pores (Laschke et al., 2014b) . Histological analyses of freshly seeded scaffolds revealed that the microvascular fragments were randomly distributed on the scaffolds' surface and in the centre pores (Fig. 1a) .
Dorsal skinfold chamber model
The effect of MALP-2 on the vascularisation of microvesselseeded scaffolds was analysed in the dorsal skinfold chamber model by means of intravital fluorescence microscopy (Fig. 1b) . A detailed description of the chamber preparation is given by Laschke et al. (2011) . The animals were allowed to recover from the preparation for 48 h prior to the treatment of the chamber tissue with MALP-2 and the implantation of the scaffolds.
MALP-2 (MALP-2 Research, Braunschweig, Germany) was kept frozen at −20 °C as a stock solution of 1 mg/mL in 30 % isopropanol. For the experiments the stock solution was diluted with 0.9 % NaCl to reach a final dose of 0.5 µg MALP-2 dissolved in 150 µL (3.3 µg/mL). This dose has previously been shown to induce a strong angiogenic host tissue reaction to implanted scaffolds in the dorsal skinfold chamber (Laschke et al., 2014a) . After removal of the cover glass, MALP-2 or vehicle was topically applied onto the exposed striated muscle tissue of the chamber for 30 min. Subsequently, one scaffold seeded with microvascular fragments was centrally placed into the MALP-2 or vehicle without prior rinsing of the chamber tissue (Fig. 1c) , so that the solutions could also be absorbed into the pores of the implant. After sealing the observation window with a new cover class, intravital fluorescence microscopy was repetitively performed over two weeks, as described previously in detail (Laschke et al., 2014b) (Fig. 1d,e) . For this purpose, 0.05 mL 5 % fluorescein isothiocyanate (FITC)-labelled dextran 150,000 (Sigma-Aldrich, Taufkirchen, Germany) and 0.05 mL 0.1 % rhodamine 6G (Sigma-Aldrich) were injected i.v. via the retrobulbary space of the anaesthetised mice. The two vital dyes were administered for contrast enhancement by staining of blood plasma (Debergh et al., 2015) and for direct in vivo staining of leukocytes (Baatz et al., 1995; MALP-2 and microvascular fragments Herr et al., 2015) . The microscopic images were recorded by a charge-coupled device video camera (FK6990; Pieper, Schwerte, Germany) and transferred to a DVD system for off-line analysis.
Microcirculatory analysis
The microscopic images were analysed with CapImage (Zeintl, Heidelberg, Germany). The vascularisation of the scaffolds was assessed at a magnification of ×460 in 8 different microvascular regions of interest (ROIs) within the implants. Perfused ROIs (given in % of all analysed ROIs) were defined as areas, which exhibited either newly developed red blood cell (RBC)-perfused microvessels or reperfused microvascular fragments. In addition, the functional microvessel density, i.e. the length of all RBC-perfused blood vessels per ROI, was assessed C Grässer et al.
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and is given in cm/cm² (Laschke et al., 2012) . Finally, we measured the diameter (d; given in µm) and the centreline RBC velocity (v; given in µm/s) of 25 randomly selected microvessels in the centre of the implants, which already exhibited a blood perfusion at the time point of analysis. The wall shear rate (y; given in s -1 ) of these vessels was then calculated based on the Newtonian definition: y = 8 * v/d (Kremer et al., 2008) .
Leukocyte-endothelial cell interaction was analysed at a ×460 magnification in 4 different microvascular regions of interest (ROIs) next to the implants. For this purpose, rhodamine 6G-stained rolling leukocytes and adherent leukocytes were quantified in 1-3 postcapillary or collecting venules per ROI. Rolling leukocytes were defined as cells moving with a velocity less than two-fifth of the centreline velocity. They are expressed as the number of cells per minute that passed a reference point within the microvessel (Hoffmann et al., 2004) . Adherent leukocytes were defined as cells that did not move or detach from the endothelial lining within a 20 s observation period. They are expressed as number of cells per mm 2 of venular endothelial surface assuming cylindrical vessel geometry (Hoffmann et al., 2004) . Finally, the diameter, centreline RBC velocity and wall shear rate of the venules were determined.
Experimental protocol
Microvascular fragments were isolated from the epididymal fat pads of 6 male wild-type C57BL/6 mice. Directly after the isolation procedure, we assessed the number of microvascular fragments from 2 donor animals by brightfield microscopy. The microvascular fragments of the other 4 animals were seeded on 4 scaffolds, which were then directly processed for the histological assessment of the seeding quality without in vivo implantation.
Microvascular fragments from the epididymal fat pads of 14 C57BL/6 donor mice were seeded on 14 scaffolds. Subsequently, the scaffolds were implanted into the dorsal skinfold chambers of 14 C57BL/6 recipient mice, which were exposed to MALP-2 (n = 7 biological replicates) or vehicle (control; n = 7 biological replicates). Intravital fluorescence microscopy was performed immediately after implantation (day 0) as well as at day 3, 6, 10 and 14. At the end of the in vivo experiments, the animals were sacrificed with an overdose of the anaesthetics and the dorsal skinfold chamber preparations were excised for histological and immunohistochemical analyses.
In an additional set of in vitro experiments, microvascular fragments were isolated from the epididymal fat pads of 10 C57BL/6 donor mice and cultured for 24 h in 24-well plates containing 500 µL endothelial cell growth medium MV (EC medium; PromoCell, Heidelberg, Germany) supplemented with 3.3 µg/mL MALP-2 or vehicle. Subsequently, the fragments were embedded in 1 % agarose (Sigma-Aldrich) and further processed for immunohistochemical analyses.
Histology and immunohistochemistry
Formalin-fixed specimens of freshly seeded scaffolds and dorsal skinfold preparations with scaffold implants were embedded in paraffin and cut into 3 µm-thick sections.
Haematoxylin and eosin (HE) staining of individual sections was performed according to standard procedures.
For immunohistochemical analyses, paraffin-embedded 3 µm-thick sections were stained with a monoclonal ratanti-mouse antibody against CD31 (6 µg/mL; Dianova GmbH, Hamburg, Germany) and with a polyclonal rabbit-anti-mouse antibody against cleaved caspase-3 (0.63 µg/mL; New England Biolabs, Frankfurt am Main, Germany). A goat-anti-rat IgG-Cy3 antibody (4.5 µg/mL; Dianova GmbH), a goat-anti-rat IgG-Alexa488 antibody (20 µg/mL; Invitrogen, Eugene, OR, USA) and a goat-antirabbit IgG-biotinylated antibody (ready-to-use; Abcam) served as secondary antibodies. The biotinylated antibody was detected by Cy3-labeled-streptavidin (50 µg/mL; Invitrogen). On each section, cell nuclei were stained with Hoechst 33342 (2 µg/mL; Sigma-Aldrich) to merge the images exactly. The sections were examined using a BX60 microscope (Olympus, Hamburg, Germany). Quantitative analyses of the sections included the determination of the microvessel density (CD31-stained cells; given in mm −2 ) in the border and centre of the implanted scaffolds. Moreover, we assessed the fraction (given in %) of cleaved caspase-3-positive endothelial and perivascular cells in microvascular fragments, which were cultured for 24 h in EC medium supplemented with MALP-2 or vehicle.
Statistics
After testing the data for normal distribution and equal variance, differences between the two groups were analysed by the unpaired Student's t-test. To test for time effects in the individual groups, ANOVA for repeated measures was applied. This was followed by the StudentNewman-Keuls test, including the correction of the alpha error according to Bonferroni probabilities to compensate for multiple comparisons (SigmaPlot 11.0; Systat Software Inc., San Jose, CA, USA). All values are expressed as means ± SEM. Statistical significance was accepted for a value of p < 0.05.
Results
Inflammatory tissue response to MALP-2
To assess the inflammatory response to locally applied MALP-2, we first analysed the leukocyte-endothelial cell interaction in postcapillary and collecting venules of the chamber tissue by means of intravital fluorescence microscopy. Throughout the observation period of 14 d, the analysed vessels exhibited a comparable diameter, centreline RBC velocity and shear rate without significant differences between MALP-2-treated and vehicle-treated chambers (Table 1) .
Stimulation of the chamber tissue with MALP-2 did not affect the number of rolling leukocytes, which ranged between 22-33 min −1 in vehicle-treated and MALP-2-treated venules without significant differences (Fig. 2c) . In contrast, MALP-2 markedly increased the number of adherent leukocytes during the first 3 d after application when compared to vehicle-treated controls (Figs. 2a,b,d ). The number of adherent leukocytes was even higher
MALP-2 and microvascular fragments than 600 mm −2 at the day of scaffold implantation, which indicates strong tissue inflammation in the dorsal skinfold chamber model (Rücker et al., 2006) . However, this inflammatory tissue response was only of short duration. Thereafter, numbers of adherent leukocytes returned to physiological levels < 200 mm −2 , which are typical for non-inflamed chamber tissue (Rücker et al., 2006; Laschke et al., 2010) .
Vascularisation of implanted scaffolds
To assess the effect of MALP-2 on the vascularisation capacity of the microvascular fragments within the polyurethane scaffolds, we analysed the number of perfused ROIs and the functional microvessel density in central surface areas of the implants. In previous studies, we implanted scaffolds seeded with microvascular fragments from transgenic green fluorescent protein (GFP)-positive donor mice in the dorsal skinfold chamber of GFP-negative wild-type recipient animals (Laschke et al., 2012; Laschke et al., 2015) . By this, we could demonstrate that the vascularisation in these central surface areas of the implants originates nearly exclusively from the microvascular fragments and not from ingrowing microvessels of the surrounding host tissue.
In vehicle-treated and MALP-2-treated chambers first perfused microvessels could be detected in the scaffolds' centre at day 6 after implantation ( Fig. 3c,d ). This indicates that, to this time point, the microvascular fragments had developed interconnections to the blood-supplying microvessels of the implantation site. Throughout the further time course of the experiment, an increasing number of vascular sprouts grew out of the perfused microvessels, finally resulting in the formation of new microvascular networks within the implanted scaffolds. Unexpectedly, this process was markedly altered in MALP-2-treated chambers. The scaffolds exposed to MALP-2 exhibited a delayed perfusion, as indicated by a significantly reduced number of perfused ROIs at day 10 when compared to vehicle-treated controls (Fig. 3c) . In addition, the functional microvessel density within these scaffolds was significantly lower at day 10 and 14 after implantation (Fig.  3a,b,d ).
Additional micro-haemodynamic analyses revealed that at day 6 the re-perfused microvascular fragments exhibited comparable diameters of ~ 60 µm within the scaffolds of the two groups (Fig. 4c) . During the following days, the vessel diameters progressively decreased until day 14 as a typical sign of vessel stabilisation and vascular remodelling. Of interest, this decrease was less pronounced in the MALP-2-treated chambers (Fig. 4a-c) . Moreover, at day 14 centreline RBC velocities and shear rates were significantly lower in the newly formed microvascular networks of scaffolds within MALP-2-treated chambers when compared to controls (Fig. 4d,e) .
Incorporation of scaffolds into the surrounding host tissue
Histological analyses of the dorsal skinfold chamber preparations at day 14 showed that the scaffolds were surrounded by a newly formed granulation tissue, which also grew into the pores of the implants (Fig. 5a,b) . This ingrowth was less pronounced in the scaffolds of MALP-2-treated chambers, indicating a deteriorated incorporation of the implants when compared to controls.
Additional immunohistochemical analyses revealed a significantly higher density of CD31-positive microvessels at the border of scaffolds in MALP-2-treated chambers (Fig. 5c-e) . This shows that the treatment with MALP-2 stimulated angiogenesis in the granulation tissue in direct vicinity to the implants. However, the number of CD31-positive microvessels was significantly lower in the scaffolds' centre when compared to controls . This finding is in line with our intravital fluorescent microscopic results, indicating an impaired vascularisation capacity of microvascular fragments exposed to MALP-2.
Effect of MALP-2 on cell viability in microvascular fragments
Microvascular fragments are free of adipocytes, because they are destroyed during the enzymatic isolation procedure ) of postcapillary and collecting venules in close vicinity of microvessel-seeded scaffolds directly (0 d) as well as 3, 6, 10 and 14 d after implantation into the dorsal skinfold chambers, as assessed by intravital fluorescence microscopy and computer-assisted off-line analysis. The chamber tissue was exposed to MALP-2 (n = 7) or vehicle (control; n = 7) 30 min before implantation of the scaffolds. Mean ± SEM. ) (d) in venules within vehicle-treated (white bars, n = 7) and MALP-2-treated (black bars, n = 7) dorsal skinfold chambers directly (d0) as well as at day 3, 6, 10 and 14 after scaffold implantation, as assessed by intravital fluorescence microscopy and computer-assisted off-line analysis. Means ± SEM. ) (e) of microvessels in polyurethane scaffolds at day 6, 10 and 14 after implantation into vehicle-treated (control; white circles, n = 7) and MALP-2-treated (black circles, n = 7) dorsal skinfold chambers, as assessed by intravital fluorescence microscopy and computer-assisted off-line analysis. Means ± SEM. ) in the border and centre of microvessel-seeded polyurethane scaffolds at day 14 after implantation into vehicle-treated (control; white bars, n = 7) and MALP-2-treated (black bars, n = 7) dorsal skinfold chambers, as assessed by immunohistochemistry. Means ± SEM. *p < 0.05 vs. control.
centre border C Grässer et al. MALP-2 and microvascular fragments Laschke et al., 2012) . However, beside endothelial cells, microvascular fragments still exhibit a mixture of different perivascular cell types, including vessel wall-stabilising pericytes, endothelial progenitor cells and mesenchymal stem cells within their physiological niche (Laschke et al., 2012; McDaniel et al., 2014) . In an additional set of in vitro experiments, we quantified the number of cleaved caspase-3-positive apoptotic endothelial and perivascular cells in isolated microvascular fragments, which had been cultured for 24 h in EC medium supplemented with MALP-2 or vehicle. Of interest, we found that exposure to MALP-2 significantly increased both the number of apoptotic endothelial and perivascular cells when compared to vehicle-treated controls (Fig. 6a-c) .
Discussion
In the present study, we analysed the effects of MALP-2 on the vascularisation of polyurethane scaffolds seeded with adipose tissue-derived microvascular fragments.
Previously, we could demonstrate that these fragments can be used as effective vascularisation units in tissue engineering, which develop into new microvascular networks within implanted scaffolds (Laschke et al., 2012; Laschke et al., 2014b) . This process, however, takes several days. During this time period the cells inside the implants may suffer from critical hypoxia. On the other hand, we have recently shown that local application of MALP-2 is a promising strategy to improve the angiogenic host tissue response to implanted biomaterials (Laschke et al., 2014a) . Hence, we herein speculated that this approach may accelerate and enhance the vascularisation of microvessel-seeded scaffolds. Unexpectedly, we found that despite an improved vascularisation at the implantation site exposure to MALP-2 impaired the development of new microvascular networks within the scaffolds. By means of intravital fluorescence microscopy, we repetitively analysed leukocyte-endothelial cell interactions to characterise the inflammatory host tissue response in venules of MALP-2-treated and vehicle-treated dorsal skinfold chambers. In the two experimental groups, these venules exhibited comparable diameters, centreline RBC velocities and wall shear rates. This indicates that differences in leukocyte-endothelial cell interactions are not due to different micro-haemodynamic conditions. In
MALP-2 and microvascular fragments line with our previous study (Laschke et al., 2014a) , local application of MALP-2 induced a temporary inflammation of the host site, which was restricted to the first 3 d after scaffold implantation. This may have contributed to the improved vascularisation of the granulation tissue developing around the scaffolds during the 14-day implantation period. In fact, accumulation of leukocytes and macrophages at inflammatory sites is typically associated with the local release of pro-angiogenic growth factors, which stimulate the development of new blood vessels (David Dong et al., 2009; Kreuger and Phillipson, 2016) . On the other hand, MALP-2 is not only a potent stimulator of the immune system, but has also been shown to exert direct angiogenic effects. (Grote et al., 2010) reported that TLR2/6-dependent stimulation of endothelial cells by MALP-2 promotes their proliferation, migration and tube forming capacity. They further found that these effects can also be induced by MALP-2-stimulated MSCs, which secrete high amounts of angiogenic growth factors, such as VEGF (Grote et al., 2013b) . Accordingly, tissue-resident MSCs may support MALP-2-induced angiogenesis in a paracrine manner. Microvascular fragments seeded on implanted scaffolds have to reassemble to new microvascular networks. They also have to develop interconnections to the microvessels of the surrounding host tissue for the onset of an own blood supply. These are typical angiogenic processes, which are characterised by sprout formation, vessel growth and vascular remodelling. However, despite its pro-angiogenic properties, MALP-2 did not promote these processes. In fact, we found that microvascular fragment-seeded scaffolds exposed to MALP-2 exhibited a significantly reduced number of perfused ROIs and a lower functional microvessel density when compared to vehicle-treated controls. This was associated with less tissue ingrowth into the implants. We additionally found that vessel maturation and vascular remodelling was markedly impaired in the implants, as indicated by a delayed diameter reduction and deteriorated blood perfusion of the newly developing microvascular networks (Vollmar et al., 2001) . Accordingly, wall shear rates were reduced in these networks when compared to controls. This, in turn, may have contributed to a deteriorated scaffold vascularisation, because shear stress is well known to be a driving force of angiogenesis (Brown and Hudlicka, 2003; Resnick et al., 2003) .
To unravel the mechanisms underlying the detrimental effects of MALP-2 on microvascular fragments, we additionally analysed the viability of isolated microvascular fragments, which had been cultured for 24 h in EC medium supplemented with MALP-2 or vehicle. We could demonstrate that MALP-2-treated microvascular fragments exhibit a significantly increased number of apoptotic endothelial and perivascular cells when compared to vehicle-treated controls. This observation is in line with the findings of . They reported that MALP-2 activates nuclear factor (NF)-κB in cultured HEK293 cells, followed by p38 mitogen activated protein kinase (MAPK)-mediated apoptosis. Hence, we suggest that this pro-apoptotic effect of MALP-2 may have markedly affected the vascularisation capacity of microvascular fragments in our in vivo experiments. Of interest, this was not associated with the induction of apoptotic cell death in the host microvasculature, as indicated by an improved vascularisation of the granulation tissue surrounding the MALP-2-treated implants. These discrepant observations may be explained by the fact that the microvascular fragments underwent an enzymatic isolation procedure and suffered from hypoxia in the initial phase after scaffold implantation. In addition, it is well known that microvascular blood flow and shear forces are essential for endothelial cell homeostasis (Chien 2007; Weber et al., 2010) . Cessation of blood flow, as it is the case in freshly isolated microvascular fragments, promotes endothelial cell apoptosis (Meeson et al., 1996) . Taken together, these additional stresses may have substantially increased the susceptibility of the microvascular fragments to the pro-apoptotic MALP-2 stimulus when compared to the host microvessels, which were protected within their physiological environment.
Conclusions
We could demonstrate in the present study that local treatment of the implantation site with MALP-2 improves the angiogenic host tissue response to polyurethane scaffolds. However, MALP-2 treatment impaired the capacity of adipose tissue-derived microvascular fragments to develop into new microvascular networks within the implants. Accordingly, the herein evaluated approach may not be recommended to further improve the vascularisation capacity of microvascular fragments in tissue engineering applications.
